
Opinion|Videos|December 6, 2024
The Role of BTK Inhibitors in the Evolving CSU Treatment Landscape
Key Takeaways
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors are reshaping the evolving treatment landscape for chronic spontaneous urticaria (CSU) by providing targeted therapeutic options that address underlying mast cell activation.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
2
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
3
What We Still Don't Know: Gaps, Phototherapy, and the Future of Pediatric Eczema Care
4
When and How to Escalate Pediatric Atopic Dermatitis Treatment
5





















































